Free tool
FAERS Monitor: Augtyro
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 218213 or its brand name (Augtyro, Repotrectinib). Reports on generic versions are filed under their own applications.
Reports
274
Serious
174
64% of reports
Hospitalization
68
Death reported
36
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- dizziness44
- death28
- nausea21
- off label use19
- neuropathy peripheral18
- fatigue13
- adverse event12
- pain12
- muscular weakness11
- paraesthesia10
- balance disorder9
- diarrhoea9
- gait disturbance9
- pulmonary embolism9
- anaemia8
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2022 | 2 |
| 2024 | 100 |
| 2025 | 114 |
| 2026 | 58 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,053,885 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| neuropathy peripheralSignal | 18 | 14.5 | 9.3 | 214 |
| adverse eventSignal | 12 | 10.0 | 5.7 | 89 |
| balance disorderSignal | 9 | 8.0 | 4.2 | 48 |
| muscular weaknessSignal | 11 | 7.4 | 4.2 | 55 |
| pulmonary embolismSignal | 9 | 7.3 | 3.8 | 43 |
| dizzinessSignal | 44 | 6.8 | 5.2 | 216 |
| paraesthesiaSignal | 10 | 4.9 | 2.7 | 27 |
| gait disturbanceSignal | 9 | 3.6 | 1.9 | 15 |
| anaemiaSignal | 8 | 3.2 | 1.6 | 10 |
| deathSignal | 28 | 2.5 | 1.8 | 25 |
| nauseaSignal | 21 | 2.0 | 1.4 | 10 |
| off label use | 19 | 1.7 | 1.1 | 5 |
| pain | 12 | 1.5 | 0.9 | 2 |
| fatigue | 13 | 1.3 | 0.8 | 1 |
| diarrhoea | 9 | 1.1 | 0.6 | 0 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.